Quizartinib is an anti-cancer drug that is used to treat adults with relapsed or refractory acute myeloid leukemia (AML). It is a type of drug called a tyrosine kinase inhibitor, which works by blocking a protein called FLT3, which is found in some types of cancer cells. By blocking this protein, Quizartinib helps to slow down or stop the growth of cancer cells. Quizartinib is usually given as a pill and is taken once daily. Common side effects of Quizartinib include nausea, vomiting, diarrhea, fatigue, anemia, decreased appetite, and headache.
Quizartinib is an anti-cancer medication used specifically to treat a certain type of acute myeloid leukemia (AML) [1]. Here's a detailed breakdown of its use:
- Type of Cancer: Acute Myeloid Leukemia (AML) with a specific gene mutation called FLT3 internal tandem duplication (ITD) [1, 2].
- Mechanism of Action: Quizartinib is a FLT3 inhibitor. It targets and blocks a protein called FLT3 that plays a role in the growth and survival of abnormal leukemia cells with the FLT3-ITD mutation [2, 3]. By inhibiting FLT3, quizartinib helps stop the growth and spread of these cancerous cells.
- Uses: Quizartinib is typically used in combination with standard chemotherapy for newly diagnosed AML patients who have the FLT3-ITD mutation [1]. It can be used during the induction and consolidation phases of chemotherapy, followed by maintenance therapy with quizartinib alone [2].
Key points to remember about Quizartinib:
- It's only approved and effective for AML with the specific FLT3-ITD mutation. A doctor will perform a test to confirm this mutation before prescribing quizartinib [1].
- It's typically an oral medication taken in tablet form [2].
- Like many medications, quizartinib can cause side effects. Some common ones include diarrhea, nausea, fatigue, and QT prolongation (a heart rhythm issue) [2]. It's important to discuss potential side effects with your doctor.
- Quizartinib can interact with other medications, so it's crucial to inform your doctor about all medications you're taking before starting quizartinib treatment [2].